Table 1.
Comparison of ICs exerting immune regulatory versus immune pathological functions
| Immune regulatory functions | Pathological functions | References | |
|---|---|---|---|
| Components | Ag and high-affinity Ab | Ag and low-affinity Ab | 27 |
| Deposit on vessels/binding to FcγR | – Ag:Ab in circulation; – Size, subclasses, glycosylation of IgG determine IC binding to FcγR; |
– Ag:Ab cannot be cleared by phagocytosis; – Deposited on blood vessels and organs; |
30, 45 |
| Immunological outcomes | – Interact with DC, enhance Ag presentation; – Induce effective T-cell-mediated immune responses; – Induce high titer broadly reactive antibodies; – Reshape intracellular responses; |
– Trigger ADCC, ADCP, CPC; – Intrinsic ADE; – Activate CD16+ monocyte (SLE); – Inflammation; – Pathological lesions; |
29, 47, 48, 55– 58, 63, 64, 66, 99 |
| Biological/medical implementation | Generate broadly neutralizing antibodies, develop new vaccines | New targets and drug development | 79, 86, 91 |